Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/114888
Title: COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study
Authors: Papiris, Spyros A.
Campo, Ilaria
Mariani, Francesca
Kallieri, Maria
Kolilekas, Lykourgos
Papaioannou, Andriana I.
Gonca Chousein, Efsun
Cetinkaya, Erdogan
Bonella, Francesco
Borie, Raphael
Kokosi, Maria
Pickworth, Thomas
Molina-Molina, Maria
Gasa, Mercè
Radzikowska, Elżbieta
Fijolek, Justyna
Jouneau, Stéphane
Gomez, Emmanuel
McCarthy, Cormac
Bendstrup, Elisabeth
Piotrowski, Wojciech J
Pabary, Rishi
Hadchouel, Alice
Coolen-Allou, Nathalie
Alfaro, Tiago M. 
Robalo Cordeiro, Carlos
Antonogiannaki, Elvira-Markela
Tomos, Ioannis P.
Papakosta, Despoina
Kontakiotis, Theodoros
Panagiotou, Panagiota
Douros, Konstantinos
Schams, Andrea
Lettieri, Sara
Papaevangelou, Vassiliki
Kanaka-Gantenbein, Christina
Karakatsani, Anna
Loukides, Stelios
Costabel, Ulrich
Crestani, Bruno
Morgan, Cliff
Tazawa, Ryushi
Bush, Andrew
Griese, Matthias
Manali, Effrosyni D.
Issue Date: Jan-2023
Project: S.A. Papiris reports grants, personal fees and nonfinancial support from La Roche Hoffman and Boehringer Ingelheim, and other support from Savara, outside the submitted work. F. Bonella reports grants and personal fees from Savara Pharma outside the submitted work. R. Borie has received consulting fees from Boehringer Ingelheim, Roche and Sanofi, outside the submitted work; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim and Roche, outside the submitted work; support for attending meetings and/or travel received from Boehringer Ingelheim, Roche and Chiesi outside the submitted work; and participation on a data safety monitoring or advisory board for Savara, outside the submitted work. M. Molina-Molina reports personal fees and grants from Esteve-Teijin, Roche and Boehringer Ingelheim, outside the submitted work. E. Jouneau reports personal fees and other support from Actelion, AIRB, AstraZeneca, Bellerophon Therapeutics, Biogen, BMS, Boehringer Ingelheim, Chiesi, FibroGen, Galecto Biotech, Genzyme, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pharm-Olam, Pfizer, Pliant Therapeutics, F. Hoffmann-La Roche, Ltd, Sanofi and Savara-Serendex, outside the submitted work. C. McCarthy is a scientific advisory board member of Savara Inc. unrelated to this work and has not received any payment from Savara Inc. for any work to date. E. Bendstrup reports grants and personal fees from Boehringer Ingelheim and Hofmann la Roche, and personal fees from Galapagos, outside the submitted work. M. Griese has received grants or contracts from Boehringer Ingelheim, outside the submitted work; has participated on a data safety or advisory board for Boehringer Ingelheim, outside the submitted work; and is the Head of chILD-EU, outside the submitted work. E.D. Manali reports personal fees and nonfinancial support from La Roche Hoffman; grants, personal fees and nonfinancial support from Boehringer Ingelheim; and other support from Savara, all outside the submitted work. The remaining authors have nothing to disclose. 
Volume: 9
Issue: 1
Abstract: Adult PAP patients experience similar #COVID19 rates to the general population, and high rates of hospitalisation and deaths, underscoring their vulnerability and the need for measures to prevent infection. The impact of iGM-CSF must be considered. https://bit.ly/3M0wKnZ.
URI: https://hdl.handle.net/10316/114888
ISSN: 2312-0541
DOI: 10.1183/23120541.00199-2022
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais

Show full item record

Page view(s)

15
checked on Apr 24, 2024

Download(s)

6
checked on Apr 24, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons